Will TRI disclose CoCounsel-specific ARR or ACV by end of 2026?

Management actively declined analyst requests for CoCounsel-specific ARR in Q4 2025 — this is a deliberate policy, not an oversight. Companies typically resist creating narrowly tracked product metrics because they constrain future bundling flexibility and create quarter-to-quarter comparison pressure. TRI's strategy of reporting GenAI-enabled ACV as a percentage gives them narrative benefit without the specificity risk. The 69% controlling shareholder structure reduces accountability pressure to disclose. Three quarters remains a short window to reverse a deliberate non-disclosure policy.

The information economics strongly favor non-disclosure. If CoCounsel ARR is impressive, management benefits more from the mystique and market's AI premium than from a specific number that creates a new quarterly benchmark. If it is modest relative to user count (1M users generating, say, $100M ARR), disclosure would deflate the narrative. Either way, management has rational incentive to maintain opacity. The most likely disclosure catalyst would be competitive pressure (e.g., a legal tech competitor disclosing superior metrics) or a strategic pivot to usage-based pricing requiring revenue composition transparency.

While the base case is continued non-disclosure, there are scenarios where disclosure happens. If CoCounsel ARR crosses a psychologically meaningful threshold (e.g., $500M+), management may choose to disclose as a 'milestone' to justify the premium multiple and silence bears. Also, the upcoming CFO transition creates a moment where new financial frameworks could be introduced, and new CFOs sometimes seek to establish credibility through enhanced transparency. The probability is low but non-trivial given the 9-month window.

Management has been crystal clear: they decline to provide CoCounsel-specific metrics. This wasn't a dodge — it was a deliberate response to an analyst question. Companies rarely reverse disclosure policies within 3 quarters absent a major strategic shift. The controlling shareholder structure means no activist can force disclosure. The GenAI-enabled ACV percentage gives enough AI narrative fuel without the commitment of product-level ARR. NO is the strong base case.

Strong conviction on NO. The only way disclosure happens is if: (1) a competitor forces it by disclosing superior metrics, (2) CoCounsel hits a milestone so large that non-disclosure becomes more suspicious than disclosure, or (3) regulatory requirements change. None of these are likely within 9 months. Management has a working narrative strategy that does not require product-level disclosure. The CFO transition is an edge case but new CFOs typically continue existing disclosure frameworks initially.

Base case is clearly non-disclosure, but giving slightly more weight to the CFO transition catalyst. A new CFO establishing credibility through enhanced transparency is a recognized pattern in corporate finance. If the new CFO is appointed in mid-2026 and wants to signal a fresh approach, product-level AI metrics would be a low-risk way to build analyst goodwill. Still unlikely within the timeframe but not negligible.

Management explicitly declined disclosure in Q4 2025. 69% controlling shareholder means no external pressure. GenAI ACV % serves the narrative. No catalyst for reversal in 9 months. Strong NO.

Non-disclosure is the clear base case. The 9-month window is too short for most catalysts (competitive pressure, regulatory change). CFO transition is a minor positive but unlikely to trigger immediate disclosure change. Still, CoCounsel at 1M users is a large scale — at some point disclosure becomes inevitable, but probably not in 2026.

All evidence points to continued non-disclosure. Management has a deliberate policy, faces no external pressure due to controlling shareholder structure, and has a working alternative metric (GenAI ACV %). Low probability but not zero given CFO transition window.